Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novo Nordisk A/S (NVO) vs Somnigroup International Inc. Common Stock (SGI) Price & Performance

Novo Nordisk A/STrade
Somnigroup International Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Novo Nordisk A/S vs Somnigroup International Inc. Common Stock — how do they compare? Novo Nordisk A/S trades at $37.79 (market cap $169.08B), while Somnigroup International Inc. Common Stock trades at $62 (market cap $14.48B). The key difference: Novo Nordisk A/S is far larger — about 11.7× Somnigroup International Inc. Common Stock's market cap, and Novo Nordisk A/S pays the higher dividend (4.72%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Somnigroup International Inc. Common Stock for 0 Days on average.

NVOSGI
Market Cap
$169.08B$14.48B
Volume
9,259,1521,734,399
Sector
HealthConsumer Cyclical
52-Week High
$63.98$97.99
52-Week Low
$35.29$61.49
Typical Hold Time
116 Days0 Days
Enterprise Value
$183.28B$20.78B
Dividend Yield
4.72%1.08%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $38.12, down 1.19% with bearish technical signals despite strong fundamentals. The company reported Q2 2026 EPS of $0.96, beating expectations by 17%, continuing a trend of earnings outperformance. Valuation metrics remain attractive with P/E of 9.67 and ROE of 59.82%, while recent news highlights pipeline expansion through $4 billion in licensing deals and progress on oral Wegovy formulations.

The stock presents a compelling value opportunity with strong profitability and growth prospects in obesity/diabetes markets, though technical weakness and competitive pressure from Eli Lilly create near-term headwinds. Analyst consensus remains bullish with $42.33 price target representing 11% upside potential from current levels.

Somnigroup International Inc. Common Stock

Somnigroup International (SGI) trades at $62.87, up 0.75% with neutral technical signals. The company shows strong profitability with 44.24% gross margins and has beaten earnings estimates for three consecutive quarters. Recent acquisition of Leggett & Platt enhances vertical integration with $75M synergy target. Analyst consensus is strongly bullish with 91% buy ratings and $94.50 price target, representing 50% upside potential from current levels.

SGI presents compelling growth prospects through strategic acquisitions and operational efficiencies, though faces margin pressures in weak bedding markets. The stock trades at reasonable valuations (P/E 24.85) with improving cash flow trends expected in 2026. Key risks include integration execution and market competition, but strong institutional interest and insider buying support the bullish case.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NVO
68% Buy32% Sell
Avg holding period · 116 Days
SGI
100% Buy0% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO →

About Somnigroup International Inc. Common Stock

Somnigroup International Inc. (formerly Tempur Sealy International) is a bedding and sleep-products company that designs, manufactures, distributes, and retails mattresses and related products. It operates through Tempur Sealy North America, Tempur Sealy International, and Mattress Firm, with brands including Tempur-Pedic, Sealy, Stearns & Foster, and Mattress Firm.

Read more on SGI →